Abstract
Massive genomic analyses have underscored the diversity of chronic lymphocytic leukaemia (CLL) between patients. Genetic heterogeneity of tumour clones within a patient may fuel tumour evolution. Several recurrently deregulated intra-cellular pathways are candidates for targeted therapies that are very promising and are dramatically changing clinical patients’ perspectives. In this review we present an overview of the genetic and epigenetic features of CLL and their clinical and biological implications.
Original language | English |
---|---|
Pages (from-to) | 852-870 |
Number of pages | 19 |
Journal | British Journal of Haematology |
Volume | 178 |
Issue number | 6 |
DOIs | |
Publication status | Published - 1 Sept 2017 |
Keywords
- chronic lymphocytic leukaemia
- mutations
- targeted therapy
- tumour evolution